Ouvrier–Billson Syndrome

Ouvrier–Billson syndrome is a rare neuro-ophthalmic condition in babies and young children. During “spells,” the child’s eyes hold a fixed upward gaze, often for minutes to hours. Looking down is jerky (down-beat saccades), but side-to-side eye movement stays normal. Many children tip the chin downward to see better. Episodes tend to be worse when the child is tired, sick, or in bright light and often improve after sleep. Most children improve over months to a few years, and many recover completely. Some children also have ataxia (wobbly balance) or mild developmental delay; doctors investigate other causes if red flags are present. This syndrome was first described by Ouvrier and Billson in 1988, and later reviews confirmed the key features and generally benign course. PubMed+3PubMed+3PubMed+3 PTU is likely heterogeneous. Most babies have normal brain scans and tests. In a minority, genetic variants—especially in CACNA1A and occasionally GRID2/SEPSECS—are linked with PTU-like episodes, often with ataxia or other neurologic signs. PMC

Ouvrier–Billson syndrome is a rare eye–movement and balance disorder that starts in infancy. During short spells (called “paroxysms”), a baby’s eyes suddenly point upward and stay there for a while. The baby often drops their chin to look forward from “under” their eyes. Horizontal eye movement usually stays normal. Many children also look a little unsteady or wobbly when they try to sit, stand, or walk (ataxia). The episodes are not seizures, and awareness is typically normal. They often get better with sleep and can become worse with tiredness or illness. In most children, the condition improves on its own over months to a few years. This syndrome was first described by pediatric neurologists Ouvrier and Billson in 1988. SAGE Journals+2Pediatric Neurology Briefs+2

Researchers now consider Ouvrier–Billson syndrome to be the same clinical entity as paroxysmal tonic upgaze (PTU) of childhood, sometimes with ataxia. PTU has been linked to several genes in some families, and in other cases no cause is found. Because a persistent upgaze can rarely be caused by a brainstem or cerebellar lesion, brain imaging is usually recommended at diagnosis to be safe. Orpha.net+2PMC+2

---

Other names

• Paroxysmal tonic upgaze (PTU) of childhood

• Benign paroxysmal tonic upgaze

• Paroxysmal tonic upward gaze

• Benign paroxysmal tonic upgaze with ataxia

All these terms refer to the same core syndrome first detailed by Ouvrier & Billson. “Benign” is often used because most children improve spontaneously, but doctors still check for treatable look-alike conditions. SAGE Journals+2PubMed+2

---

Types

1. Idiopathic PTU
   This is the most common form: the classic upgaze spells begin in the first year of life in an otherwise healthy child, and episodes fade with time. No structural brain problem or single gene cause is found. PubMed

2. PTU with ataxia
   Here, the upgaze spells come with noticeable unsteadiness. It can still resolve, but the ataxia prompts careful evaluation (imaging and sometimes genetics). Orpha.net

3. Genetic PTU (channelopathy or synaptopathy–associated)
   In a subset, mutations in CACNA1A (and less commonly GRID2, SEPSECS, CACNA1G) are found. These children may also have other paroxysmal symptoms (e.g., torticollis), migraine-like episodes, or developmental delay. PMC

4. Secondary PTU (due to structural/other causes)
   Rarely, PTU-like upgaze is from a brainstem or cerebellar lesion or another neurological disease; this is why an MRI is recommended at the start. Pediatric Neurology Briefs

---

Possible causes and associated factors

PTU often has no single cause. Doctors think of “causes or associations” as things that can produce the same look of sustained upgaze. Below are factors reported in medical literature; a given child typically has only one or a few of these.

1. Normal brain development variant (idiopathic) – Many infants have PTU with normal tests and gradual, spontaneous recovery, suggesting a benign developmental phenomenon of the oculomotor system. PubMed

2. Immaturity of brainstem gaze circuits – Delayed maturation of pathways that hold the eyes steady may produce upgaze spells that resolve as the circuits mature. PubMed

3. Genetic variants in CACNA1A – Pathogenic changes in this calcium-channel gene can cause PTU with or without ataxia or other paroxysmal events. PubMed+1

4. Genetic variants in GRID2 – A synaptic receptor gene linked with cerebellar dysfunction; PTU has been reported with GRID2 changes. PMC

5. Genetic variants in SEPSECS – Mutations in a tRNA-related gene have been reported in PTU presentations. PMC

6. Genetic variants in CACNA1G – A T-type calcium channel gene; de novo CACNA1G variants have been described in infants with PTU and congenital ataxia. ScienceDirect

7. Cerebellar involvement (functional or structural) – The cerebellum coordinates eye movements; dysfunction here can present with upgaze and downbeat nystagmus. Orpha.net

8. Brainstem lesions (rare but important) – Space-occupying processes affecting vertical gaze centers can mimic PTU; this is why MRI is advised, especially when ataxia is present. Pediatric Neurology Briefs

9. Neurotransmitter imbalance or depletion (hypothesis) – Proposed mechanism in some cases to explain the paroxysmal, fatigue-sensitive nature. PubMed

10. Immune dysregulation (hypothesis) – Suggested in a few reports; thought to transiently disturb ocular motor control. PubMed

11. Family clustering – Familial cases imply inherited susceptibility even when a single gene is not identified. PubMed

12. Fatigue – Not a root cause but a trigger that worsens spells in many children. PubMed

13. Intercurrent illness (fever, infections) – Another trigger that can increase frequency/severity of upgaze episodes. ScienceDirect

14. Sleep–wake modulation – Spells often improve with sleep, suggesting physiologic modulation of circuits. PubMed

15. Association with benign paroxysmal torticollis – Some CACNA1A-related children show both PTU and episodic torticollis. jaapos.org

16. Association with other CACNA1A paroxysmal disorders – e.g., episodic ataxia, hemiplegic migraine–like events in the same child or family. Children’s Hospital of Philadelphia

17. Downbeat nystagmus on downgaze – A sign (not a cause) that often accompanies PTU and points clinicians toward cerebellar pathways. SAGE Journals

18. Developmental delay (co-occurrence in genetic cases) – In some gene-positive children, motor or language delay is present alongside PTU. PubMed

19. Fetal valproate exposure (reported association) – Mentioned in reviews of PTU cases; highlights the need to review prenatal history. Pediatric Neurology Briefs

20. Heterogeneous, multifactorial nature – Overall, PTU is best viewed as a syndrome that can arise from several different pathways; many children remain idiopathic and recover. ScienceDirect

---

Common symptoms and signs

1. Sudden upward eye position – Eyes drift up and hold there for seconds to hours during an episode; between spells the gaze can be normal. SAGE Journals

2. Chin-down head posture – Children often flex the neck to see forward from beneath the raised eyes. ScienceDirect

3. Normal sideways (horizontal) eye movements – Side-to-side movement is usually preserved, helping doctors distinguish PTU from other disorders. rarediseases.info.nih.gov

4. Downbeat saccades on attempted downgaze – When trying to look down, quick downward corrections may appear. SAGE Journals

5. Vertical nystagmus – Small up-and-down eye oscillations can occur, especially with attempts to change gaze. rarediseases.info.nih.gov

6. Ataxia (unsteady movements) – Some children wobble when sitting, standing, or walking, especially during episodes. Orpha.net

7. Torticollis or abnormal head tilt (in some) – Brief head tilts or neck turning can accompany spells, particularly in CACNA1A-related cases. PMC

8. Ictal behaviors (rare, gene-linked) – Stereotyped hand movements or pallor can occur in gene-positive PTU. PMC

9. Irritability during spells – Babies may seem fussy while trying to stabilize their vision. (Descriptive clinical reports.) Wikipedia

10. Worsening with fatigue or illness – Episodes are longer or more frequent when the child is tired or sick. PubMed+1

11. Improvement with sleep – Naps or nighttime sleep often reset the eyes to a normal position. PubMed

12. Normal consciousness – Children remain awake and responsive, helping differentiate PTU from many seizures. PubMed

13. Onset before 12 months – Most children present in the first year of life. rareshare.org

14. Fluctuating course – Spells can cluster for weeks and then fade; many remit by early childhood. PubMed

15. Developmental delay in a subset – Especially in genetic or cerebellar forms; prompts a broader work-up. PubMed

---

Diagnostic tests

A) Physical examination & bedside observation

1. Structured neurological exam – Checks alertness, tone, reflexes, and coordination to spot ataxia or other signs that might suggest a structural or genetic cause. Orpha.net

2. Eye movement exam in all gaze positions – Confirms sustained upward deviation with preserved horizontal movement; looks for downbeat saccades on downgaze. SAGE Journals

3. Head-posture assessment – Notes habitual chin-down posture that helps the child see during spells. ScienceDirect

4. Spell triggers and sleep response review – Clinician documents worsening with fatigue/illness and relief with sleep—key diagnostic clues. PubMed+1

B) “Manual” or focused bedside tests

5. Fixation and tracking tests – Gentle tracking of a toy/light right, left, up, and down helps document preserved horizontal movement and limited downgaze during an episode. rarediseases.info.nih.gov

6. Downgaze saccade observation – Asking the child to look down (when possible) reveals characteristic downbeat saccades. SAGE Journals

7. Head-tilt and chin-tuck maneuvers – Watching how posture changes vision can help confirm PTU patterns and distinguish from vestibular problems. ScienceDirect

8. Video documentation (home or clinic) – Short videos of spells are extremely useful for diagnosis and for excluding seizures or tics. Wikipedia

C) Laboratory / pathological tests (mainly to rule out mimics)

9. Basic metabolic panel and glucose – Screens for metabolic contributors to episodic neurologic symptoms. (General diagnostic practice in paroxysmal pediatric disorders.) PubMed

10. Thyroid function tests – Broad exclusion of metabolic contributors to eye movement abnormalities or hypotonia in infants when clinically indicated. (General approach.) PubMed

11. Inflammatory/autoimmune screening when suggested by history – Used selectively if there are red flags for immune causes (fever, regression). PubMed

12. Review of prenatal drug exposures – Specifically note valproate exposure given reported associations in PTU literature. Pediatric Neurology Briefs

D) Electrodiagnostic tests

13. Standard EEG – PTU is non-epileptic; a normal EEG during spells helps separate it from seizure disorders. JournalAgent

14. Video-EEG monitoring (if diagnosis uncertain) – Captures both behavior and brainwaves to exclude subtle seizures that can mimic upgaze episodes. JournalAgent

15. Visual evoked potentials (VEP) when indicated – Rarely used; can assess visual pathway integrity if there are unusual visual concerns. (General pediatric neuro-ophthalmology practice.) Orpha.net

E) Imaging tests

16. Brain MRI (with attention to brainstem & cerebellum) – The key imaging study to rule out space-occupying or malformative lesions in vertical gaze pathways. Recommended especially if ataxia or other focal signs are present. Pediatric Neurology Briefs

17. MRI with diffusion and posterior fossa sequences – Adds sensitivity for small brainstem/cerebellar abnormalities relevant to vertical gaze control. Pediatric Neurology Briefs

18. MR spectroscopy (select cases) – Occasionally used in complex evaluations to look for metabolic patterns in the cerebellum/brainstem. (General practice in pediatric neurology.) Orpha.net

19. Spinal imaging (rare, if exam suggests) – Considered only if clinical signs point beyond the brain (usually not needed for classic PTU). Orpha.net

F) Genetic testing

20. Targeted gene panel or exome sequencing – Looks for CACNA1A, GRID2, SEPSECS, CACNA1G and related genes when symptoms are persistent, atypical, or accompanied by ataxia, developmental delay, or other paroxysmal events. PubMed+2PMC+2p

Non-pharmacological treatments (therapies & supports)

Reminder: These supports aim to reduce episode burden, improve safety, and aid development. They don’t “cure” the condition, but they often help while the disorder runs its course.

1. Parental education & reassurance
   Purpose: Reduce fear, teach benign nature and typical course.
   Mechanism: Understanding that most children improve and that spells often ease with sleep lowers anxiety, prevents unnecessary emergency visits, and supports consistent routines. rarediseases.info.nih.gov+1

2. Sleep optimization (regular naps/bedtime)
   Purpose: Cut fatigue-related triggers.
   Mechanism: Sleep often aborts episodes; consistent schedules reduce spell frequency linked to overtiredness. PubMed

3. Treat intercurrent illness promptly (fever control)
   Purpose: Febrile illnesses can worsen spells.
   Mechanism: Managing fever and hydration reduces physiologic stress that precipitates PTU episodes. PubMed

4. Light management (soft indoor lighting, hats outdoors)
   Purpose: Reduce photic triggers.
   Mechanism: Lowering glare may lessen sensory provocation of spells (reported clinically in PTU case series). Lippincott Journals

5. Calm, predictable routines
   Purpose: Limit stress triggers.
   Mechanism: Stable daily rhythms dampen autonomic arousal that can exacerbate dystonic eye postures. Lippincott Journals

6. Video documentation of episodes
   Purpose: Help clinicians confirm PTU vs. seizures or ocular motor palsy.
   Mechanism: High-quality home videos capture eye positions and chin-down compensation; they guide diagnosis and avoid unnecessary treatments. PMC

7. Physiotherapy for balance/ataxia (if present)
   Purpose: Improve gait stability and motor milestones.
   Mechanism: Task-specific balance training enhances cerebellar compensation and reduces falls. rarediseases.info.nih.gov

8. Occupational therapy (fine-motor & visual-motor integration)
   Purpose: Support development if mild delays exist.
   Mechanism: Repetitive, graded activities strengthen neural networks for hand-eye skills that can lag in some children with PTU. PubMed

9. Developmental surveillance & early intervention
   Purpose: Catch and address speech, language, or cognitive delays early.
   Mechanism: Regular screens and referral improve long-term outcomes where delays coexist. PubMed

10. Vision/orthoptics review
    Purpose: Identify coexisting ocular motility issues.
    Mechanism: Orthoptic strategies and follow-up mitigate strabismus or nystagmus found in a subset at follow-up. PubMed

11. Safe play environment & fall prevention
    Purpose: Reduce injury risk during spells or ataxic phases.
    Mechanism: Soft flooring, corner guards, and supervised play decrease harm when gaze locks upward.

12. Hydration & regular meals
    Purpose: Prevent fatigue and physiologic stress that can trigger episodes.
    Mechanism: Stable glucose and fluid status support autonomic balance.

13. Temperature regulation
    Purpose: Avoid overheating, which may worsen symptoms.
    Mechanism: Cool breaks and breathable clothing limit stress responses.

14. Illness action plan
    Purpose: Give caregivers steps during colds/fevers.
    Mechanism: Early antipyresis, rest, and fluids can shorten exacerbations. PubMed

15. School/daycare liaison
    Purpose: Ensure staff recognize benign spells and handle safely.
    Mechanism: Written plans prevent mislabeling as seizures.

16. Neurology follow-up schedule
    Purpose: Reassess red flags and stop unnecessary meds.
    Mechanism: PTU can mimic other disorders; scheduled reviews maintain diagnostic vigilance. Pediatric Neurology Briefs

17. MRI/EEG only when indicated by red flags
    Purpose: Exclude brainstem lesions or epileptic events if atypical features appear.
    Mechanism: Imaging/EEG rule out other causes when clinical picture is not classic. Pediatric Neurology Briefs+1

18. Genetic counseling/testing (select cases)
    Purpose: If PTU coexists with ataxia/developmental issues or family history.
    Mechanism: Identifies CACNA1A/GRID2/SEPSECS variants that shape prognosis and family planning. PMC

19. Caregiver support networks
    Purpose: Reduce stress and share coping strategies.
    Mechanism: Peer support improves adherence to routines and mitigates anxiety.

20. Sunset review for medication need
    Purpose: Most cases remit—avoid long-term unnecessary therapy.
    Mechanism: Regularly taper/stop off-label meds once symptoms resolve. rarediseases.info.nih.gov

---

Drug treatments

Key safety truth: There are no FDA-approved medications for PTU. Some children have been reported to improve with levodopa or acetazolamide, but responses vary and other series found no clear benefit from several agents (e.g., ACTH, some antiseizure drugs). Any use is off-label and specialist-guided. PubMed+2Pediatrics Publications+2

Because the user asked for “20 drug treatments from accessdata.fda.gov,” I cannot fabricate FDA-approved PTU drugs. Instead, here are the few agents actually discussed in the PTU literature, with transparent labeling as off-label for PTU:

1) Levodopa (off-label for PTU)
Class: Dopaminergic agent.
Dose/Timing (typical pediatric dystonia ranges, individualized by specialists): Often started low (e.g., 1–3 mg/kg/day of levodopa component divided), titrated by response.
Purpose: Trial when spells are frequent/severe or when a dystonia spectrum is suspected.
Mechanism: Supplements central dopamine; in a classic 1988 report, one child’s PTU improved with levodopa, suggesting a dopaminergic modulation of ocular motor control.
Side effects: Nausea, irritability, sleep changes; rare dyskinesia at higher doses—requires close monitoring. PubMed

2) Acetazolamide (off-label for PTU)
Class: Carbonic anhydrase inhibitor.
Dose (reported cases): Clinicians use weight-based dosing; titration guided by response and bicarbonate.
Purpose: Consider in PTU with ataxia or when CACNA1A-related episodic features are suspected.
Mechanism: Mild metabolic acidosis can stabilize neuronal firing; multiple case reports/series (including CACNA1A-related PTU) showed dose-responsive reduction in spells; some experts note variable efficacy.
Side effects: Paresthesias, appetite loss, fatigue; monitor electrolytes and bicarbonate. PubMed+2American Academy of Neurology+2

3) Antiseizure medicines (general comment; not typically helpful for classic PTU)
Class: Various (e.g., valproate, levetiracetam).
Use: Only if EEG/video-EEG proves epileptic spells or if another epilepsy syndrome coexists.
Mechanism/Reasoning: PTU itself is nonepileptic; antiseizure drugs are not indicated unless seizures are documented. Some series reported no benefit in classic PTU.
Risks: Drug-specific (sedation, behavioral effects, lab monitoring). PMC+1

4) ACTH/corticosteroids (not recommended for classic PTU)
Reason: Reviews note no benefit for PTU itself; avoid steroid toxicity without clear indication. Pediatrics Publications

No other medications have consistent evidence for PTU. Any additional pharmacotherapy should target comorbidities (e.g., migraine prophylaxis in confirmed CACNA1A disorders) under specialist care. Children’s Hospital of Philadelphia

---

Dietary molecular supplements

These do not treat PTU specifically; they support overall brain and child health. Use only with pediatric guidance, especially in infants.

1. Omega-3 fatty acids (DHA/EPA) – brain membrane support; typical toddler doses from fish oil; may aid general neurodevelopment.

2. Vitamin D – bone/immune health; correct deficiency per pediatric targets.

3. Iron (if deficient) – supports myelination and attention; screen before giving.

4. Vitamin B12/folate (if low) – methylation and myelin synthesis; replace documented deficiency.

5. Choline – phospholipid precursor; present in eggs/fortified foods.

6. Iodine – thyroid hormone synthesis; ensure adequate iodized salt use.

7. Zinc – enzymatic/immune functions; avoid excess.

8. Magnesium – neuronal excitability; foods first (nuts/greens); supplements only if needed.

9. Protein-rich diet – provides essential amino acids for growth/neurotransmitters.

10. Antioxidant-rich fruits/vegetables – general neuroprotective milieu.

(Evidence is general pediatric nutrition; no PTU-specific trials.)

---

Immunity-booster / regenerative / stem-cell” drugs

There are no regenerative or stem-cell drugs for PTU. Using such therapies for PTU would be experimental and not recommended. For completeness (and honesty), here’s what is appropriate:

1. Vaccinations (routine childhood schedule) – support immune system against infections that can exacerbate spells; not a “drug for PTU,” but essential preventive care.

2. Vitamin D (if deficient) – supports normal immune function; correct deficiency under guidance.

3. Iron (if deficient) – restores normal hematologic/immune support; deficiency treatment only.

4. Probiotics (food-based or supplements with pediatric approval) – gut health; modest immunomodulatory effects; not PTU therapy.

5. No stem-cell therapy – not indicated; no evidence in PTU.

6. No “immune boosters” beyond standard pediatric care – avoid unproven products.

---

Surgeries

Surgery is not a treatment for classic PTU/Ouvrier–Billson syndrome. However, doctors may consider procedures only if evaluation finds another condition that mimics PTU:

1. Posterior fossa decompression – Why: If MRI reveals Chiari malformation causing downbeat nystagmus/vertical gaze issues. Not for idiopathic PTU.

2. Hydrocephalus shunting (VP shunt/ETV) – Why: If raised intracranial pressure or obstructive hydrocephalus is the real cause of ocular findings.

3. Tumor resection – Why: If a brainstem mass is identified (PTU-like signs can occur with lesions).

4. Strabismus surgery – Why: Rarely, for persistent ocular misalignment unrelated to PTU after remission.

5. Biopsy/other neurosurgical diagnostics – Why: Only when imaging shows atypical pathology.

In typical PTU with normal studies, none of the above are indicated. Pediatric Neurology Briefs

---

Preventions

1. Keep regular sleep and nap schedules. PubMed

2. Treat fevers quickly; hydrate during illnesses. PubMed

3. Avoid overtiredness and long stretches without breaks. Lippincott Journals

4. Use soft lighting; brimmed hats outdoors.

5. Maintain balanced meals and fluids.

6. Create safe play areas to prevent falls.

7. Keep illness action plans handy for caregivers.

8. Schedule regular follow-ups with neurology/ophthalmology. Pediatric Neurology Briefs

9. Seek early therapies if development lags. PubMed

10. Consider genetic counseling when red flags/family history present. PMC

---

When to see a doctor (or go to the ER)

• First episodes of sustained upward gaze, especially under 12 months of age. PubMed

• Red flags: persistent vomiting, loss of consciousness, seizures, weakness, new abnormal eye movements, severe ataxia, developmental regression, or no relief with sleep. PMC

• Any change in pattern—more frequent/longer spells—or new neurologic signs.

• If a clinician suggests medicines, ensure it’s under pediatric neurology guidance (off-label use). Pediatrics Publications

---

What to eat & what to avoid

Eat:

• Regular, balanced meals (whole grains, fruits, vegetables, lean protein, healthy fats).

• Iron- and B-vitamin–rich foods (meats, beans, leafy greens, fortified cereals) if diet is limited.

• Hydration—water and breastmilk/formula/age-appropriate milk.

Avoid/limit:

• Excess sugar/caffeine (if offered to toddlers) that may worsen sleep.

• Highly processed snacks displacing nutrient-dense foods.

• Unproven supplements advertised as “curing” eye disorders.

(Diet supports general health; no food cures PTU.)

---

Frequently asked questions (FAQs)

1) Is Ouvrier–Billson syndrome dangerous?
Usually no. Most children improve spontaneously over 1–2 years; doctors monitor for red flags and other causes. rarediseases.info.nih.gov

2) Is it epilepsy?
No—PTU episodes are nonepileptic. When the story is atypical, doctors may do EEG or video-EEG to rule out seizures. PMC

3) Will my child outgrow it?
Many do. The average remission is in early childhood, often by ~2–3 years, though timelines vary. PubMed

4) Why does sleep help?
Sleep reduces neural excitability and breaks the dystonic eye posture; classic descriptions note relief after sleep. PubMed

5) Can infections make it worse?
Yes. Fevers/illness can exacerbate spells; prompt fever control and rest help. PubMed

6) Do we need an MRI?
If the presentation is classic and the exam is otherwise normal, many clinicians observe. MRI is indicated when red flags suggest another cause (e.g., brainstem lesion). Pediatric Neurology Briefs

7) Are there genes linked to PTU?
Yes, especially CACNA1A (and sometimes GRID2/SEPSECS) in children with additional neurologic signs. Genetic testing is selective, not routine for every child. PMC

8) Do medicines cure PTU?
No. There’s no FDA-approved PTU drug. Off-label levodopa or acetazolamide sometimes help; responses vary and side effects require monitoring. PubMed+1

9) Do anti-seizure drugs help?
Not for classic PTU. They are used only if the child also has proven seizures. Pediatrics Publications+1

10) Could this affect learning or motor skills?
Some cohorts report developmental or ocular motility issues at follow-up. Early therapies and monitoring support best outcomes. PubMed

11) Is PTU part of a migraine/ataxia spectrum?
In some CACNA1A cases, PTU clusters with episodic ataxia or other paroxysmal disorders. Children’s Hospital of Philadelphia

12) Can we prevent episodes?
You can reduce them: prioritize sleep, manage illnesses/fever, avoid overtiredness, and minimize glare. PubMed

13) Will my child need surgery?
Not for PTU itself. Surgery is only for other diagnoses discovered on evaluation. Pediatric Neurology Briefs

14) Should we change diet?
No special diet treats PTU. Aim for balanced nutrition; treat true deficiencies.

15) Where can I read more?
Original and review sources: Ouvrier & Billson (1988); subsequent reviews and case series; NIH/ORD and NORD summaries. PubMed+2rarediseases.info.nih.gov+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 21, 2025.

PDF Documents For This Disease Condition References